Expanding Oncology Portfolio with Breakthrough Science On December 30, 2025, Johnson & Johnson (J&J) announced the completion of its acquisition of clinical-stage biotech firm Halda Therapeutics. The $3.05 billion all-cash transaction underscores J&J’s strategic commitment to reinforcing its oncology pipeline through transformative drug delivery platforms.
Harnessing the RIPTAC Platform The acquisition centers on Halda’s proprietary RIPTAC (Regulated Induced Proximity Targeting Chimera) technology. This platform facilitates the development of oral therapies designed to precisely target cancer cells in solid tumors:
-
Prostate Cancer Treatment: The lead candidate, HLD-0915, is a clinical-stage, once-daily oral therapy designed to overcome existing resistance mechanisms in prostate cancer.
-
Pipeline Diversity: The deal adds early-stage candidates for lung and breast cancers. J&J indicated that the RIPTAC platform’s versatility allows for potential therapeutic applications beyond oncology.
Financial Impact and Outlook J&J expects the acquisition to result in an adjusted earnings per share (EPS) dilution of approximately $0.20, split equally between 2025 and 2026. These charges reflect integration costs, financing, and Halda employee equity settlements. J&J executives highlighted that integrating Halda’s team and technology will accelerate the discovery of novel molecules aimed at redefining the standard of cancer care.
Source: https://www.pharmaceutical-technology.com/news/johnson-johnson-acquires-halda/?cf-view